Grastim pfs

Grastim is a medication used to treat neutropenia (a low white blood cell count) caused by cancer treatment or other conditions. It is an injectable medication that works by stimulating the production of white blood cells, which helps to fight off infections.

Composition:

Grastim contains Filgrastim, a medication that is a granulocyte-colony stimulating factor (G-CSF).

Indications:

Grastim is indicated for the treatment of:

1. Neutropenia (low white blood cell count) in patients with non-myeloid malignancies (cancers) receiving chemotherapy
2. Severe chronic neutropenia (a condition characterized by a persistent low white blood cell count)

Mechanism of Action:

Filgrastim works by:

1. Stimulating the production of white blood cells, including neutrophils, in the bone marrow
2. Increasing the release of white blood cells from the bone marrow into the bloodstream

Dosage and Administration:

The recommended dosage of Grastim is:

• 5-10 mcg/kg/day subcutaneously (under the skin) or intramuscularly (into the muscle)
• The dose should be adjusted based on the patient’s response to treatment and laboratory tests

Side Effects:

Common side effects of Grastim include:

1. Bone pain
2. Headache
3. Fatigue
4. Nausea and vomiting
5. Diarrhea
6. Skin rash
7. Local reactions at the injection site

Serious side effects can include:

1. Anaphylaxis (a severe allergic reaction)
2. Hypersensitivity reactions
3. Severe allergic reactions
4. Increased risk of infections

Contraindications:

Grastim is contraindicated in patients with:

1. Hypersensitivity to Filgrastim or other G-CSF medications
2. Severe hypersensitivity reactions to human granulocyte-colony stimulating factor (hG-CSF)

Precautions:

1. Patients with a history of severe allergic reactions should be closely monitored while receiving Grastim.
2. Patients with a history of cardiovascular disease should be closely monitored while receiving Grastim.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of bone pain or headache.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store at room temperature (20°C to 25°C) and protected from light.
• Do not freeze or expose to direct sunlight.
• Use within 24 months of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.